The Role of p53 Tumor Suppressor Gene in Human Head and Neck Tumorigenesis

References

• Parkin D M, Laara E, Muir C S. Estimates of the worldwide frequency of the sixteen major cancers in 1980. Int J Cancer 1988; 41: 184–97
   PubMed Web of Science ®Google Scholar
• Boring C C, Squires T S, Tong T. Cancer statistics, 1993. Cancer J Clin 1993; 43: 7–26
   PubMed Web of Science ®Google Scholar
• Klein G. The approaching era of the tumor suppressor genes. Science 1987; 238: 1539–45
   PubMed Web of Science ®Google Scholar
• Seizinger B R, Breakefield X O. The role of “tumor suppressor” genes in neural tumors. Trends Neurosci 1990; 13: 3–6
   PubMed Web of Science ®Google Scholar
• De Mars R. 23rd Annual Symposium on Fundamental Cancer Research. Williams and Wilkins, Baltimore, Baltimore 1970; 105–6
   Google Scholar
• Knudson A G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci 1971; 68: 820–3
   PubMed Web of Science ®Google Scholar
• Cavenne W K, Dryja T P, Phillips R A, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779–84
   PubMedGoogle Scholar
• Li F P. Cancer families: human models of susceptibility to neoplasia. Cancer Res 1988; 48: 5381–6
   PubMedGoogle Scholar
• Malkin D, Li F P, Strong L C, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233–1238
   PubMed Web of Science ®Google Scholar
• Srivastava S, Zou Z, Pirollo K, Blattner W, Chang E H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747–9
   PubMed Web of Science ®Google Scholar
• Levine A J. The p53 tumor suppressor gene and product. Tumor Suppressor Genes, the cell cycle and cancer, A J Levine, L M Frank. Cold Spring Harbor Press, New York 1992; L59–79
   Google Scholar
• Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699–703
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sindransky D, Volgelstein B, Harris C C. P53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Field J K, Pavelic Z P, Spandidos D A, Stambrook P J, Jones A S, Gluckman J L. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993; 119: 1118–22
   PubMedGoogle Scholar
• Brachman D G, Graves D, Bokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992; 52: 4832–6
   PubMedGoogle Scholar
• Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992; 7: 927–33
   PubMed Web of Science ®Google Scholar
• Maestro R, Dolcetti R, Gasparoto D, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992; 7: 1159–66
   PubMed Web of Science ®Google Scholar
• Somers K D, Merrick M A, Lopez M E, Incognito L A, Schechter G L, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992; 52: 5997–6000
   PubMed Web of Science ®Google Scholar
• Fearon E R. Genetic alterations underlying colorectal tumorigenesis. Tumor suppressor genes, the cell cycle and cancer, A J Levine, L M Frank. Cold Spring Harbor Press, New York 1992; 119–36
   Google Scholar
• Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67
   PubMed Web of Science ®Google Scholar
• Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589–600
   PubMed Web of Science ®Google Scholar
• Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665–9
   PubMed Web of Science ®Google Scholar
• Hollstein M C, Smits A M, Galiana C, et al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 1988; 48: 5119–23
   PubMed Web of Science ®Google Scholar
• Jiang W, Kahn S M, Guillem J G, Lu S H, Weinstein I B. Rapid detection of ras oncogenes in human tumors: application to colon, esophageal, and gastric cancer. Oncogene 1989; 4: 923–8
   PubMed Web of Science ®Google Scholar
• Hollstein M C, Metcalf R A, Welsh J A, Montesano R, Harris C C. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990; 87: 9958–61
   PubMedGoogle Scholar
• Gusterson B A, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991; 6: 1785–1789
   PubMed Web of Science ®Google Scholar
• Boyle J O, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477–80
   PubMed Web of Science ®Google Scholar
• Shim D M, Kim J, Ro J Y, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321–6
   PubMedGoogle Scholar
• Pavelic Z P, Li Y Q, Stambrook P J, et al. Overexpression of p53 protein is common in premalignant head and neck lesions. Anticancer Res 1994; 14: 2259–66
   PubMedGoogle Scholar
• Li Y Q, Pavelic Z P, Wang L J, et al. Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients. J Clin Pathol Mol Pathol 1995; 48: M269–72
   Google Scholar
• Brachman D G, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992; 52: 4832–4836
   PubMedGoogle Scholar
• Leonard H J, Kearsley J H, Chenevix-Trench G, Hayward N K. Analysis of gene amplification in head-and-neck squamous-cell carcinomas. Int J Cancer 1991; 48: 511–5
   PubMed Web of Science ®Google Scholar
• Lammie G A, Fantl V, Smith R, et al. 118287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinoma and linked to BCL-1. Oncogene 1991; 6: 439–44
   PubMedGoogle Scholar
• Motokura T, Bloom T, Kim H G, et al. A novel cyclin encoded by a bcl-1-linked candidate oncogene. Nature 1991; 350: 512–5
   PubMed Web of Science ®Google Scholar
• Rosenberg C L, Kim H G, Shows T B, Kronenberg H M, Arnold A. Rearrangement and overexpression of DlIS287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 1991; 6: 449–53
   PubMedGoogle Scholar
• Lane D P, Crawfore L V. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278: 261–3
   PubMed Web of Science ®Google Scholar
• Linzer D IM, Maltzman W, Levine A J. The SV40 a gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology 1979; 98: 308–18
   PubMed Web of Science ®Google Scholar
• Sarrow P, Mo Y S, Williams J, Levine A J. Adenovirus E1B-58 kd tumor antigen and SV40 large T antigen are physically associated with the same 54 kd protein in transformed cells. Cell 1992; 28: 387–94
   Google Scholar
• Yew P R, Berk A J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357: 82–5
   PubMed Web of Science ®Google Scholar
• Zur Hausen H. Viruses in human cancer. Science 1991; 254: 1167–73
   PubMed Web of Science ®Google Scholar
• Oliner J D, Kinzler K W, Melzer P S, George D L, Vogelstein B. Amplification of gene encoding a p53-as-sociated protein in human sarcoma. Nature 1992; 358: 80–5
   PubMed Web of Science ®Google Scholar